Related Experiment Video
Updated: Dec 27, 2025

A High-throughput Calcium-flux Assay to Study NMDA-receptors with Sensitivity to Glycine/D-serine and Glutamate
Published on: July 10, 2018
Targeting Synaptic NMDA Receptor Co-agonism as a Therapy for Alzheimer's Disease?
1UK Dementia Research Institute at the University of Edinburgh, Chancellor's Building, Edinburgh Medical School, Edinburgh EH16 4SB, UK; Centre for Discovery Brain Sciences, University of Edinburgh, Hugh Robson Building, George Square, Edinburgh EH8 9XD, UK.
Abstract:
Alzheimer's disease (AD) is associated with lower brain glucose metabolism. In this issue, Le Douce et al. (2020) show that this leads to insufficient astrocyte-dependent production of D-serine, co-agonist of synaptic NMDA receptors. Oral L-serine therapy rescues NMDA receptor hypofunction, plasticity, and cognition in an AD model, suggesting a new therapeutic strategy.
Related Concept Videos
Alzheimer's Disease: Treatment
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
Ligand-Gated Ion Channel Receptor: Gating Mechanism
Antiepileptic Drugs: Glutamate Antagonists
Long-term Depression
Calcium Ion Concentration Mechanism
If over...

